These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23742728)

  • 1. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.
    Sabbagh M; Cummings J; Christensen D; Doody R; Farlow M; Liu L; Mackell J; Fain R
    BMC Geriatr; 2013 Jun; 13():56. PubMed ID: 23742728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
    Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
    Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study.
    Schmitt FA; Saxton J; Ferris SH; Mackell J; Sun Y
    Int J Clin Pract; 2013 Oct; 67(10):1050-6. PubMed ID: 24073978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
    Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
    Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
    Cummings J; Jones R; Wilkinson D; Lopez O; Gauthier S; Waldemar G; Zhang R; Xu Y; Sun Y; Richardson S; Mackell J
    J Alzheimers Dis; 2010; 21(3):843-51. PubMed ID: 20634594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment.
    Li W; Antuono PG; Xie C; Chen G; Jones JL; Ward BD; Franczak MB; Goveas JS; Li SJ
    Neuroimage; 2012 Apr; 60(2):1083-91. PubMed ID: 22245641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
    Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
    Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
    Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
    Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
    Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
    Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
    Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R;
    Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
    Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
    Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donepezil delays progression to AD in MCI subjects with depressive symptoms.
    Lu PH; Edland SD; Teng E; Tingus K; Petersen RC; Cummings JL;
    Neurology; 2009 Jun; 72(24):2115-21. PubMed ID: 19528519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
    Winblad B; Kilander L; Eriksson S; Minthon L; Båtsman S; Wetterholm AL; Jansson-Blixt C; Haglund A;
    Lancet; 2006 Apr; 367(9516):1057-1065. PubMed ID: 16581404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
    Homma A; Atarashi H; Kubota N; Nakai K; Takase T
    J Alzheimers Dis; 2016 Mar; 52(1):345-57. PubMed ID: 26967222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.